Trial Profile
A 27-week open-label trial to characterize the safety and tolerability of orally administered ziprasidone in children and adolescent subjects with bipolar I disorder (manic or mixed), schizophrenia or schizoaffective disorder
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 23 Feb 2021
Price :
$35
*
At a glance
- Drugs Ziprasidone (Primary)
- Indications Bipolar I disorders; Schizoaffective disorder; Schizophrenia
- Focus Adverse reactions
- Sponsors Pfizer
- 29 Apr 2008 New trial record.